Скачать с ютуб New Fragile X Clinical Trial: BK Channel Openers в хорошем качестве

New Fragile X Clinical Trial: BK Channel Openers

Discover the exciting new advances in Fragile X syndrome research, featuring insights from Rob Ring, CEO of Kaerus Bioscience. Rob shares the groundbreaking work his team is doing in collaboration with FRAXA to develop BK channel openers, a promising new treatment targeting Fragile X. While the focus is on this innovative approach, you'll also hear briefly from Dr. Mike Tranfaglia of FRAXA, who highlights the foundation's support in validating this research. Learn about the potential of BK channel openers, not only for Fragile X but also for autism and other neurodevelopmental disorders, and how these clinical trials could pave the way for transformative treatments. FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments. Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders. To learn more about FRAXA's Fragile X syndrome research, to get involved with Fragile X awareness and events or to donate to FRAXA research, visit www.fraxa.org Let's Connect Facebook:   / fraxaresearch   Instagram:   / fraxaresearch   LinkedIn:   / fraxa-research-foundation   Reddit:   / fragilexreseach   Website: https://www.fraxa.org